By Fraiser Kansteiner
Frank Clyburn is taking off to “assume a leadership opportunity with another company,” Merck said Thursday. A replacement to head up human health at Merck will be announced in the coming weeks, the company added.
read more
By Robert King
President Joe Biden endorsed splitting up his $1.75 trillion Build Back Better Act, but it remains unclear what healthcare policies could survive such a piecemeal approach.
read more
By Conor Hale
The agency had previously listed one specific type of blood collection tube in shortage—those containing the anticoagulant sodium citrate, typically identified by a light blue cap. Now, the FDA has expanded that list to include all specimen tubes.
read more
By Angus Liu
In the increasingly crowded cancer immunotherapy field, AstraZeneca’s Imfinzi has mostly been used in stage III non-small cell lung cancer. But with the right combination strategy, the PD-L1 inhibitor has promise in other tumor types, AZ’s oncology R&D head said.
read more
By Heather Landi
Women's health is now in the spotlight, and investors have been quick to put their cash into this growing market. What's next for women's health? Three executives—Hilary Coles, co-founder of Hims & Hers, Carolyn Witte, co-founder of Tia and Lynne Chou O'Keefe from Define Ventures—share their perspectives on the future of the market and why healthcare works better for everyone when it works for women.
read more
By Annalee Armstrong
It’s not often that high profile pharmaceutical executives publicly laud a direct competitor’s medicine, but that’s what’s happening these days for Pfizer’s COVID-19 antiviral Paxlovid.
read more
By Paige Minemyer
Amid the industry's telehealth boom, health insurers are putting a focus on the potential of virtual care through virtual-first plan designs.
read more
By Nick Paul Taylor
Hongming Chen has ended her long affiliation with Kala Pharmaceuticals. Having been with Kala since its origins in 2010, Chen has left the chief scientific officer post to become head of R&D at a biotech that is just starting out.
read more
By Andrea Park
In an additional effort to bring down the costs of COVID tests, Sen. Ed Markey sent another letter to test makers and retailers asking them to make the tests they make and sell more affordable.
read more
By Ben Adams
AbbVie’s blockbuster giant, Humira, is used to being top dog in the pharma industry. But it had a rude awakening in 2021, when it’s massive $20 billion annual sales figure was shattered by Pfizer’s COVID-19 vaccine. And now, AbbVie's having to settle for the final podium place in the TV pharma ad spending world.
read more
By Conor Hale
A program developed by researchers at the University of Cambridge showed it can safely help deliver insulin as it is needed—and be more effective at flattening curves in glucose readings compared to today’s devices.
read more
By Angus Liu
GlaxoSmithKline’s consumer health unit won’t be bought out by Unilever: The British consumer goods giant refused to raise its $68 billion offer. But there are questions left for both companies.
read more
